Q3:16 Health Care M&A Results: Context Is Everything
Brace yourself. The third quarter results for health care mergers and acquisitions signal a hard tap on the brakes, both in deal volume and value. That’s compared with the robust second quarter, and the same quarter a year ago. Before we go any further, though, we must note that, compared with all previous third quarters stretching back to 2000, the third quarter of 2016 doesn’t look that bad. Some 369 transactions are now on the books for Q3:16, which ranks this quarter as the second-highest in deal volume for any previous third quarter. The top-ranked third quarter, coincidently, came a year ago, when Q3:15 racked up 411 transactions. So Q3:16’s deal volume slid 10% compared with the... Read More »Radiopharmacies Now on Dealmakers’ Radar
You can’t get much more “specialty” in the specialty pharmacy business than to deal in radiopharmaceuticals. Two recent deals, announced in August, show this area is heating up. IBA Molecular, a global maker and distributor of radiopharmaceutical products, agreed to pay approximately $613 million for Mallinckrodt’s (NYSE: MNK) nuclear imaging business, including a portfolio of diagnostic imaging products. The U.S. market accounts for approximately two thirds of the division’s current annual revenues. For Mallinckrodt, the sale continues its strategic portfolio transformation, as the company evolves to handle specialty pharmaceuticals that don’t glow. IBA... Read More »Henry Schein Picks up Another Dental Distribution Service
In late August 2016, Henry Schein, Inc. (NASDAQ: HSIC) announced its seventh dental acquisition since 2014. The acquisition of Marrodent gave the global dental products giant a presence in Poland, where Marrodent distributes dental equipment and dental laboratory supplies. With this addition, Henry Schein’s dental business now has operations or affiliates in 27 countries. In 2014, Henry Schein purchased five European dental companies from Arseus NV (EBR: RCUS), as well as New Jersey-based Lincoln Dental Supply, a supplier of dental products and equipment, and France-based Sirona Direct, the dental distribution business of Sirona Dental Systems Inc. (NASDAQ: SIRO). In 2015, the... Read More »BioClinica Changes Hands as CRO Market Heats Up
The market for contract research organizations (CROs) is hot in 2016. Fourteen deals have been announced so far this year, compared with five in all of 2015, 11 in 2014 and eight in 2013. The latest deal was announced on August 22, as JLL Partners and Water Street Healthcare Partners exited their investment in BioClinica, Inc. and the UK-based private equity firm Cinven stepped in, for an undisclosed price. The original investment for the global clinical trial management company, then trading under the NASDAQ ticker symbol BIOC, was announced on January 30, 2013, for $123 million (1.6x revenue and 11.8x EBITDA). That deal included the acquisition of medical imaging company CoreLab... Read More »Specialty Pharmacy Extends Reach in Healthcare
Genoa, a QoL Healthcare Company, a leading behavioral health specialty pharmacy company, has acquired the behavioral health and residential care services division of Advanced Care Pharmacy Services, including 13 of its pharmacies in Michigan. Genoa is a portfolio company of Advent International. In November 2015, Genoa acquired 1DocWay, the nation’s largest outpatient telepsychiatry provider, for an undisclosed price. Advanced Care Pharmacy Services is a privately-held Alabama-based provider of specialized pharmacy services for a variety of care settings. Genoa’s purchase, which did not disclose a price, increases its number of Michigan-based pharmacies to 24, and 325 nationally.... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
